UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
![]() |
|||||||
|
Fusion Protein:MARK1-RHOU |
Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: MARK1-RHOU | FusionPDB ID: 51739 | FusionGDB2.0 ID: 51739 | Hgene | Tgene | Gene symbol | MARK1 | RHOU | Gene ID | 4139 | 58480 |
Gene name | microtubule affinity regulating kinase 1 | ras homolog family member U | |
Synonyms | MARK|Par-1c|Par1c | ARHU|CDC42L1|G28K|WRCH1|hG28K | |
Cytomap | 1q41 | 1q42.13 | |
Type of gene | protein-coding | protein-coding | |
Description | serine/threonine-protein kinase MARK1MAP/microtubule affinity-regulating kinase 1PAR1 homolog c | rho-related GTP-binding protein RhoU2310026M05RikCDC42-like GTPase 1GTP-binding protein SB128GTP-binding protein like 1Ryu GTPaseras homolog gene family, member Uras-like gene family member Urho GTPase-like protein ARHUwnt-1 responsive Cdc42 homo | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q9P0L2 | . | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000366917, ENST00000366918, ENST00000402574, ENST00000485104, | ENST00000493528, ENST00000366691, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 3 X 4 X 3=36 | 7 X 10 X 4=280 |
# samples | 3 | 12 | |
** MAII score | log2(3/36*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(12/280*10)=-1.22239242133645 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context (manual curation of fusion genes in FusionPDB) | PubMed: MARK1 [Title/Abstract] AND RHOU [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MARK1(220826694)-RHOU(228873420), # samples:2 MARK1(220831176)-RHOU(228873420), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. MARK1-RHOU seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | MARK1 | GO:0006468 | protein phosphorylation | 14976552 |
Hgene | MARK1 | GO:0035556 | intracellular signal transduction | 14976552 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Gene Sample Information |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | SKCM | TCGA-EE-A29D-06A | MARK1 | chr1 | 220826694 | + | RHOU | chr1 | 228873420 | + |
ChimerDB4 | SKCM | TCGA-EE-A29D-06A | MARK1 | chr1 | 220826694 | + | RHOU | chr1 | 228879032 | + |
ChimerDB4 | SKCM | TCGA-EE-A29D-06A | MARK1 | chr1 | 220831176 | - | RHOU | chr1 | 228873420 | + |
ChimerDB4 | SKCM | TCGA-EE-A29D-06A | MARK1 | chr1 | 220831176 | + | RHOU | chr1 | 228873420 | + |
Top |
Fusion ORF Analysis |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000402574 | MARK1 | chr1 | 220826694 | + | ENST00000366691 | RHOU | chr1 | 228879032 | + | 5970 | 2585 | 366 | 2603 | 745 |
ENST00000366918 | MARK1 | chr1 | 220826694 | + | ENST00000366691 | RHOU | chr1 | 228879032 | + | 5904 | 2519 | 366 | 2537 | 723 |
ENST00000366917 | MARK1 | chr1 | 220826694 | + | ENST00000366691 | RHOU | chr1 | 228879032 | + | 5639 | 2254 | 35 | 2272 | 745 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000402574 | ENST00000366691 | MARK1 | chr1 | 220826694 | + | RHOU | chr1 | 228879032 | + | 0.000489269 | 0.99951077 |
ENST00000366918 | ENST00000366691 | MARK1 | chr1 | 220826694 | + | RHOU | chr1 | 228879032 | + | 0.001170821 | 0.9988292 |
ENST00000366917 | ENST00000366691 | MARK1 | chr1 | 220826694 | + | RHOU | chr1 | 228879032 | + | 0.000428586 | 0.9995714 |
Top |
Fusion Amino Acid Sequences |
![]() |
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >51739_51739_1_MARK1-RHOU_MARK1_chr1_220826694_ENST00000366917_RHOU_chr1_228879032_ENST00000366691_length(amino acids)=745AA_BP= MSAYPGGAAAGSGSPSSSSASSSLFPPPGPLVAPPRGLREPLAPALCSRPHPFPVAPRGPHHSPAGETPARPRCPHKMSARTPLPTVNER DTENHTSVDGYTEPHIQPTKSSSRQNIPRCRNSITSATDEQPHIGNYRLQKTIGKGNFAKVKLARHVLTGREVAVKIIDKTQLNPTSLQK LFREVRIMKILNHPNIVKLFEVIETEKTLYLVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKYIVHRDLKAENLLLDGD MNIKIADFGFSNEFTVGNKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTD CENLLKKLLVLNPIKRGSLEQIMKDRWMNVGHEEEELKPYTEPDPDFNDTKRIDIMVTMGFARDEINDALINQKYDEVMATYILLGRKPP EFEGGESLSSGNLCQRSRPSSDLNNSTLQSPAHLKVQRSISANQKQRRFSDHAGPSIPPAVSYTKRPQANSVESEQKEEWDKDVARKLGS TTVGSKSEMTASPLVGPERKKSSTIPSNNVYSGGSMARRNTYVCERTTDRYVALQNGKDSSLTEMSVSSISSAGSSVASAVPSARPRHQK SMSTSGHPIKVTLPTIKDGSEAYRPGTTQRVPAASPSAHSISTATPDRTRFPRGSSSRSTFHGEQLRERRSVAYNGPPASPSHETGAFAH -------------------------------------------------------------- >51739_51739_2_MARK1-RHOU_MARK1_chr1_220826694_ENST00000366918_RHOU_chr1_228879032_ENST00000366691_length(amino acids)=723AA_BP= MSAYPGGAAAGSGSPSSSSASSSLFPPPGPLVAPPRGLREPLAPALCSRPHPFPVAPRGPHHSPAGETPARPRCPHKMSARTPLPTVNER DTENHTSVDGYTEPHIQPTKSSSRQNIPRCRNSITSATDEQPHIGNYRLQKTIGKGNFAKVKLARHVLTGREVAVKIIDKTQLNPTSLQK LFREVRIMKILNHPNIGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKYIVHRDLKAENLLLDGDMNIKIADFGFSNEFTVGNKLDT FCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKKLLVLNPIKRGSLEQI MKDRWMNVGHEEEELKPYTEPDPDFNDTKRIDIMVTMGFARDEINDALINQKYDEVMATYILLGRKPPEFEGGESLSSGNLCQRSRPSSD LNNSTLQSPAHLKVQRSISANQKQRRFSDHAGPSIPPAVSYTKRPQANSVESEQKEEWDKDVARKLGSTTVGSKSEMTASPLVGPERKKS STIPSNNVYSGGSMARRNTYVCERTTDRYVALQNGKDSSLTEMSVSSISSAGSSVASAVPSARPRHQKSMSTSGHPIKVTLPTIKDGSEA YRPGTTQRVPAASPSAHSISTATPDRTRFPRGSSSRSTFHGEQLRERRSVAYNGPPASPSHETGAFAHARRGTSTGIISKITSKFVRRMN -------------------------------------------------------------- >51739_51739_3_MARK1-RHOU_MARK1_chr1_220826694_ENST00000402574_RHOU_chr1_228879032_ENST00000366691_length(amino acids)=745AA_BP= MSAYPGGAAAGSGSPSSSSASSSLFPPPGPLVAPPRGLREPLAPALCSRPHPFPVAPRGPHHSPAGETPARPRCPHKMSARTPLPTVNER DTENHTSVDGYTEPHIQPTKSSSRQNIPRCRNSITSATDEQPHIGNYRLQKTIGKGNFAKVKLARHVLTGREVAVKIIDKTQLNPTSLQK LFREVRIMKILNHPNIVKLFEVIETEKTLYLVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKYIVHRDLKAENLLLDGD MNIKIADFGFSNEFTVGNKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTD CENLLKKLLVLNPIKRGSLEQIMKDRWMNVGHEEEELKPYTEPDPDFNDTKRIDIMVTMGFARDEINDALINQKYDEVMATYILLGRKPP EFEGGESLSSGNLCQRSRPSSDLNNSTLQSPAHLKVQRSISANQKQRRFSDHAGPSIPPAVSYTKRPQANSVESEQKEEWDKDVARKLGS TTVGSKSEMTASPLVGPERKKSSTIPSNNVYSGGSMARRNTYVCERTTDRYVALQNGKDSSLTEMSVSSISSAGSSVASAVPSARPRHQK SMSTSGHPIKVTLPTIKDGSEAYRPGTTQRVPAASPSAHSISTATPDRTRFPRGSSSRSTFHGEQLRERRSVAYNGPPASPSHETGAFAH -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:220826694/chr1:228873420) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
MARK1 | . |
FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in cell polarity and microtubule dynamics regulation. Phosphorylates DCX, MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Involved in cell polarity by phosphorylating the microtubule-associated proteins MAP2, MAP4 and MAPT/TAU at KXGS motifs, causing detachment from microtubules, and their disassembly. Involved in the regulation of neuronal migration through its dual activities in regulating cellular polarity and microtubule dynamics, possibly by phosphorylating and regulating DCX. Also acts as a positive regulator of the Wnt signaling pathway, probably by mediating phosphorylation of dishevelled proteins (DVL1, DVL2 and/or DVL3). {ECO:0000269|PubMed:11433294, ECO:0000269|PubMed:17573348, ECO:0000269|PubMed:23666762}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
![]() |
- Retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366917 | + | 16 | 18 | 325_370 | 662.6666666666666 | 796.0 | Domain | UBA |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366917 | + | 16 | 18 | 60_311 | 662.6666666666666 | 796.0 | Domain | Protein kinase |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366918 | + | 15 | 16 | 325_370 | 640.6666666666666 | 759.0 | Domain | UBA |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366918 | + | 15 | 16 | 60_311 | 640.6666666666666 | 759.0 | Domain | Protein kinase |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000402574 | + | 16 | 17 | 325_370 | 527.6666666666666 | 646.0 | Domain | UBA |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000402574 | + | 16 | 17 | 60_311 | 527.6666666666666 | 646.0 | Domain | Protein kinase |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366917 | + | 16 | 18 | 66_74 | 662.6666666666666 | 796.0 | Nucleotide binding | ATP |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366918 | + | 15 | 16 | 66_74 | 640.6666666666666 | 759.0 | Nucleotide binding | ATP |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000402574 | + | 16 | 17 | 66_74 | 527.6666666666666 | 646.0 | Nucleotide binding | ATP |
Tgene | RHOU | chr1:220826694 | chr1:228879032 | ENST00000366691 | 1 | 3 | 161_164 | 107.0 | 259.0 | Nucleotide binding | Note=GTP |
- Not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366917 | + | 16 | 18 | 746_795 | 662.6666666666666 | 796.0 | Domain | KA1 |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000366918 | + | 15 | 16 | 746_795 | 640.6666666666666 | 759.0 | Domain | KA1 |
Hgene | MARK1 | chr1:220826694 | chr1:228879032 | ENST00000402574 | + | 16 | 17 | 746_795 | 527.6666666666666 | 646.0 | Domain | KA1 |
Tgene | RHOU | chr1:220826694 | chr1:228879032 | ENST00000366691 | 1 | 3 | 26_61 | 107.0 | 259.0 | Compositional bias | Gly-rich | |
Tgene | RHOU | chr1:220826694 | chr1:228879032 | ENST00000366691 | 1 | 3 | 103_107 | 107.0 | 259.0 | Nucleotide binding | GTP | |
Tgene | RHOU | chr1:220826694 | chr1:228879032 | ENST00000366691 | 1 | 3 | 56_63 | 107.0 | 259.0 | Nucleotide binding | GTP |
Top |
Fusion Protein-Protein Interaction |
![]() |
![]() |
Gene | PPI interactors |
![]() |
Gene | STRING network |
MARK1 | |
RHOU |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to MARK1-RHOU |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to MARK1-RHOU |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |